Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 8/20 | 0.67 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.66 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.66 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.66 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.66 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.60 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1833332 | 0.88 | HSD11B1 (0.68) | HSD11B1CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL1760919 | 0.86 | HSD11B1 (0.67) | HSD11B1CHRM1CHRM2CHRM4CHRM3 | |
| Hydrochloric Acid SCHEMBL3106327 | 0.86 | HSD11B1 (0.67) | HSD11B1CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL29872667 | 0.86 | HSD11B1 (0.67) | HSD11B1CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL22587867 | 0.86 | CHRM1 (0.69) | HSD11B1CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL14515245 | 0.85 | HSD11B1 (0.61) | HSD11B1CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL4669587 | 0.84 | CHRM1 (0.91) | HSD11B1CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL14870591 | 0.84 | HSD11B1 (0.60) | HSD11B1CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL1837629 | 0.83 | CHRM1 (0.65) | HSD11B1CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL29975163 | 0.83 | HSD11B1 (0.63) | HSD11B1CHRM1CHRM2CHRM4CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9931347-B2 | Pharmaceutical compound | IOMET PHARMA LTD. (US) | 2018-04-03 | — | — | US | disclosed |
| US-9931347-B2 | Pharmaceutical compound | IOMET PHARMA LTD. (US) | 2018-04-03 | — | — | US | disclosed |
| US-20160367564-A1 | Pharmaceutical Compound | IOMET PHARMA LTD. (GB) | 2016-12-22 | — | — | US | disclosed |
| US-20160367564-A1 | Pharmaceutical Compound | IOMET PHARMA LTD. (GB) | 2016-12-22 | — | — | US | disclosed |
| US-9199976-B2 | Haematopoietic-prostaglandin D2 synthase inhibitors | THE UNIVERSITY OF QUEENSLAND (AU) | 2015-12-01 | — | — | US | disclosed |
| WO-2015082499-A2 | PHARMACEUTICAL COMPOUND | IOMET PHARMA LTD (GB) | 2015-06-11 | — | — | WO | disclosed |
| US-20130137684-A1 | HAEMATOPOIETIC-PROSTAGLANDIN D2 SYNTHASE INHIBITORS | THE UNIVERSITY OF QUEENSLAND (AU) | 2013-05-30 | — | — | US | disclosed |
| WO-2008119741-A2 | 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2008-10-09 | — | — | WO | disclosed |
| US-7332492-B2 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by NP Y5 receptor | ASTRAZENECA AB (SE) | 2008-02-19 | — | — | US | disclosed |
| US-7332492-B2 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by NP Y5 receptor | ASTRAZENECA AB (SE) | 2008-02-19 | — | — | US | disclosed |
| EP-0898568-B1 | 1-(4-PIPERIDYL)-BENZIMIDAZOLES HAVING NEUROTROPHIC ACTIVITY | NEUROSEARCH AS (DK) | 2006-10-04 | — | — | EP | disclosed |
| US-6180649-B1 | NERVOUS SYSTEM DISORDERS; ALZHEIMER'S, HUNTINGTON, PARKINSON DISEASE | NEROSEARCH A/S (DK) | 2001-01-30 | — | — | US | disclosed |
| EP-0898568-A1 | 1-(4-PIPERIDYL)-BENZIMIDAZOLES HAVING NEUROTROPHIC ACTIVITY | NEUROSEARCH A/S (DK) | 1999-03-03 | — | — | EP | disclosed |
| WO-1997040035-A1 | 1-(4-PIPERIDYL)-BENZIMIDAZOLES HAVING NEUROTROPHIC ACTIVITY | NEUROSEARCH A/S (DK) | 1997-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160367564-A1 | Pharmaceutical Compound | TDO2, IDO1, IDO2 | HSD11B1 783/4885CHRM1 82/4885CHRM2 84/4885 |
| US-20130137684-A1 | HAEMATOPOIETIC-PROSTAGLANDIN D2 SYNTHASE INHIBITORS | HPGDS, PTGES, PTGIS | HSD11B1 212/4885CHRM1 4431/4885CHRM2 4129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.